Pharvaris Presents Phase 3 Deucrictibant Data at ACAAI Meeting
Pharvaris presented Phase 3 data on deucrictibant at the ACAAI annual meeting.
Related stories
Proto Labs Reports Third-Quarter 2026 Revenue of $154.3 Million
Revenue rose 14% to $154.3 million from $135.4 million a year earlier. Net income increased to $11.8 million from $7.2 million, and diluted EPS rose to $0.48 from $0.30.
M impact | EQUITY | Oct 29, 2026, 06:41 PM UTC
US Shippers’ Freight Costs Hit Five-Year High as Demand Stalls
US shippers paid the most to move freight since 2021 in the third quarter, US Bank data shows. Higher diesel prices and fewer available truck drivers helped push rates higher.
M impact | EQUITY | Oct 29, 2026, 06:40 PM UTC
Acadian Asset Management Reports Quarterly Results
Acadian Asset Management reported results for the quarter ended September 30. The supplied text contains no financial figures.
M impact | EQUITY | Oct 29, 2026, 06:40 PM UTC
C & I Leasing Posts Q3 Gross Earnings of 12.95 Billion Naira
C & I Leasing reported Q3 group gross earnings of 12.95 billion naira and continuing-operations profit before tax of 983.5 million naira.
M impact | EQUITY | Oct 29, 2026, 06:40 PM UTC
Universal Music Group Q3 Revenue Rises 12.3%, Adjusted EBITDA 9%
Universal Music Group reported third-quarter revenue of €3.39 billion, up 12.3%, and adjusted EBITDA growth of 9%. Subscription growth, physical music sales and its Downtown acquis
M impact | EQUITY | Oct 29, 2026, 06:34 PM UTC
Weil Gotshal Plans to Wind Down Amid Partner Exodus
The prominent US law firm is planning to dissolve, setting up decisions involving its lawyers, clients and rival firms.
L impact | EQUITY | Oct 29, 2026, 06:31 PM UTC